Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder
A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD.
Sponsor: Canive, Jose M., M.D.
Listed as NCT00583193, this PHASE3 trial focuses on Posttraumatic Stress Disorders and remains ongoing. Sponsored by Canive, Jose M., M.D., it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Canive, Jose M., M.D.
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .